A fusion protein comprising a DNA binding domain operably-linked to a dimerization domain, wherein the DNA binding domain specifically binds to a response element.

The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.

Disclosed is a method for producing a recombinant protein of interest, the method being characterized in by the following steps: (a) providing a fusion protein comprising an N.sup.pro autoprotease moiety and a protein of interest moiety in inclusion bodies, (b) solubilizing the inclusion bodies, (c) allowing the fusion protein to be cleaved by the N.sup.pro autoprotease moiety under chaotropic conditions, wherein the recombinant protein of interest is cleaved from the fusion protein and wherein the recombinant protein of interest is not yet renatured or simultaneously renatured, and (d) recovering the protein of interest, optionally including a renaturing step for the protein of interest.

The invention is directed to compositions to screen for small molecule drugs that inhibit proteases, such as viral proteases, e.g., HIV proteases; and methods for making and using these compositions. The invention provides compositions and methods for identifying compositions, e.g., drug molecules, that can inhibit proteases, e.g., HIV proteases. In alternative embodiments, the invention provides cell-based assays to screen for compositions, e.g., small molecules or drugs, that inhibit or modify the activity of enzymes such as calcium-dependent protein convertases involved in HIV envelop protein processing, including cleavage of the HIV gp160 envelope precursor, resulting in gp120 and gp41 envelope products.

The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.

The present invention provides a compound exhibiting coronavirus 3CL protease inhibitory activity or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same.

Provided is a compound represented by Formula (I):

##STR00001## wherein Ring A is a ring represented by:

##STR00002## wherein X is a single bond or the like, R.sup.2 is substituted or unsubstituted aromatic carbocyclyl or the like, R.sup.3c is substituted or unsubstituted aromatic carbocyclyl or the like, R.sup.3 is substituted or unsubstituted aromatic carbocyclyl or the like, R.sup.3a is a hydrogen atom or the like, R.sup.3b is a hydrogen atom, R.sup.8a is substituted or unsubstituted aromatic carbocyclyl or the like, and R.sup.8b is a hydrogen atom or the like, R.sup.1 is a substituted or unsubstituted aromatic heterocyclyl, m is 0 or the like, R.sup.5a is each independently a hydrogen atom or the like, R.sup.5b is each independently a hydrogen atom or the like, R.sup.6 is cyano or the like, and R.sup.7a and R.sup.7b are each independently a hydrogen atom or the like, or a pharmaceutically acceptable salt of the compound.

The invention relates to genetic incorporation of 2,3-diamino propionic acid (DAP) into polypeptides, to unnatural amino acids comprising DAP, to a tRNA synthetase for charging tRNA with unnatural amino acids comprising DAP, and to methods of using the resulting polypeptides, for example in capturing substrates and/or intermediates in enzymatic reactions. The invention also relates to compounds of formula (I) or (II): ##STR00001##
or salts, solvates, tautomers, isomers or mixtures thereof.

Provided herein are methods of cell-free protein synthesis, optimised cell-free protein synthesis (CFPS) reagents and the post translational modification of the expressed proteins, to increase protein expression yields. The methods are applicable to protein expression on a microfluidic device having hydrophobic surfaces by merging droplets on the device in order to screen a selection of expression and post translational modification compositions in parallel.

The technology described herein is directed to CAR polypeptides and systems comprising repressible proteases. In combination with a specific protease inhibitor, the activity of said CAR polypeptides and systems and cells comprising them can be modulated. Also described herein are methods of using said CAR polypeptides and systems, for example to treat various diseases and disorders.

Provided herein are methods, compositions, kits and systems for regulation of peptide function. In particular, provided herein are methods, compositions, kits and systems comprising nucleic acid constructs and fusion proteins comprising chemically-activated protein domains (CAPs) that regulate the activity of a fused peptide in the presence of a ligand.